Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments

March 11, 2011 By Bio-Medicine.Org

SAN DIEGO, March 11, 2011 /PRNewswire/ — Arena Pharmaceuticals,
Inc. (Nasdaq:
ARNA
) today reported financial results for the fourth quarter
and full year ended December 31, 2010, and reviewed recent
developments.

“Our focus is working with Eisai to obtain FDA approval of
lorcaserin, preparing to submit an application for European
approval of lorcaserin, and advancing select earlier-stage research
and development programs on our own or in collaboration,” said Jack
Lief, Arena’s President and Chief Executive Officer. “Resubmitting
the lorcaserin NDA is our top priority, and we are committed to
addressing the outstanding issues to the FDA’s satisfaction.”

Arena reported a net loss in the fourth quarter of 2010 of $28.2
million, or $0.23 per share, compared to a net loss in the fourth
quarter of 2009 of $29.8 million, or $0.32 per share, and a net
loss in the full year ended December 31, 2010, of $124.5 million,
or $1.14 per share, compared to a net loss in the full year ended
December 31, 2009, of $153.2 million, or $1.82 per share.

Research and development expenses continued to decline to $16.5
million in the fourth quarter of 2010 from $21.2 million in the
fourth quarter of 2009. Research and development expenses declined
to $75.5 million in the full year ended December 31, 2010, from
$110.2 million in the full year ended December 31, 2009. This
decrease is primarily due to the completion of Arena’s lorcaserin
Phase 3 clinical trials. Arena expects its research and development
expenses to continue to decline in 2011 due to the completion of
the lorcaserin Phase 3 clinical trials, expected cost savings from
its recently announced workforce reduction and other
cost-containment measures. Research and development expenses for
all of 2010 included $3.4 million in non-cash, share-based
compensation expense, compared to $4.1 million in 2009. General and
administrative

‘/>”/>

SOURCE

Related Articles Read More >

A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies
Biotronik
FDA approves Biotronik’s programmer for implanted cardiac rhythm management devices

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech